# Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity

> **NCT05637515** · PHASE3 · COMPLETED · sponsor: **Biocon Biologics Inc.** · enrollment: 374 (actual)

## Conditions studied

- Moderate Chronic Plaque Psoriasis
- Severe Chronic Plaque Psoriasis

## Interventions

- **BIOLOGICAL:** Humira 40 MG in Prefilled Syringe
- **BIOLOGICAL:** Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe

## Key facts

- **NCT ID:** NCT05637515
- **Lead sponsor:** Biocon Biologics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-21
- **Primary completion:** 2023-09-19
- **Final completion:** 2023-09-19
- **Target enrollment:** 374 (ACTUAL)
- **Last updated:** 2024-10-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05637515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05637515, "Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05637515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*